



# RESULTS IN PHARMA SCIENCES

The new online only, open access, peer reviewed journal in Pharma Sciences

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

---

- **Description** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.2



ISSN: 2211-2863

### DESCRIPTION

---

*Results in Pharma Sciences* is an online-only, open access journal publishing peer reviewed research from all areas of **pharmaceutics** and **pharmaceutical sciences** in academia and industry, including but not limited to **pharmaceutical technology**, pharmaceuticals, **biopharmaceutics**, **pharmaceutical biotechnology**, **drug delivery**, **controlled release**, **pharmacokinetics**, and applied **medicinal chemistry**. The focus is on fast, online publication of scientifically sound science.

All papers published in *Results in Pharma Sciences* have undergone full peer review and must be: Scientifically sound In compliance with international research and publishing ethics Written in clear, concise and correct English A valid, contribution to the existing literature and of educational value to the specific community and readers Not previously published material **Benefits to authors** We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### EDITORIAL BOARD

---

#### **Managing Editor:**

#### **Advisory Board:**

**A.T. Florence**, University of London, London, UK

**R. Gurny**, Université de Genève, Geneva, Switzerland

**C.-M. Lehr, PhD**, Universität des Saarlandes, Saarbrücken, Germany

**M. Möller**, Université de Genève, Geneva, Switzerland

**M.J. Rathbone**, International Medical University, Kuala Lumpur, Malaysia

**J. Siepmann**, University of Lille, Lille, France

**A. Urtti**, University of Helsinki, Helsinki, Finland

## GUIDE FOR AUTHORS

---

### INTRODUCTION

Traditional publishing processes are changing and in this context we have established a family cluster of linked journals within the pharmaceutical sciences field. This allows us to foster collaboration between our journals, enabling us to deliver more options, faster services, and effective solutions to truly innovate and improve the manuscript submission and peer review process.

**Results in Pharma Sciences** is the new online only, author-pays, open access member of this family covering all aspects of pharmaceutical sciences. All papers published within the journal have been peer reviewed and evaluated on the basis of scientific soundness.

The family cluster is based around a new article transfer service giving authors the option, if they are unsuccessful in their original submission, to decide to have their manuscript transferred, together with reviewer reports, to another suitable pharmaceutical sciences journal or **Results in Pharma Sciences**, without the need to resubmit and reformat. **Results in Pharma Sciences** provides authors a speedy way to publish their peer reviewed science.

Journals which are part of this family include: European Journal of Pharmaceutics & Biopharmaceutics, European Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release

### Acceptance criteria

All papers published in **Results in Pharma Sciences** are peer reviewed and must be: Scientifically sound. In compliance with international research and publishing ethics. Written in clear, concise and correct English. A valid contribution to the existing literature and of educational value to the specific community and readers. Not previously published material.

### Peer-review policy

**Results in Pharma Sciences** is part of a peer review innovation called PeerChoice. PeerChoice utilizes a select group of reviewers who actively choose the manuscripts they want to review from the abstracts of submitted manuscripts. In this way, reviewers are quickly able to select manuscripts in their area of interest and expertise. As with traditional systems, your information is kept secure throughout the peer review process. Elsevier is committed to improving the publishing experience and offers PeerChoice as just one of the innovations designed to better serve the scientific community.

### Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <https://www.elsevier.com/publishingethics> and <https://www.elsevier.com/journal-authors/ethics>.

### Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, <http://www.wma.net/en/30publications/10policies/b3/index.html>; Uniform Requirements for manuscripts submitted to Biomedical journals, <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. **All animal studies need to ensure they comply with the ARRIVE guidelines.** More information can be found at <http://www.nc3rs.org.uk/page.asp?id=1357>.

### Informed consent

Investigations on human subjects must include a statement indicating that informed consent was obtained after the nature and possible consequences of the studies had been fully explained.

### *Animal welfare*

Authors using experimental animals must state that their care was in accordance with institutional guidelines. For animals subjected to invasive procedures, the anesthetic, analgesic and tranquilizing agents used, as well as the amounts and frequency of administration, must be stated.

### *Availability of materials*

Publication of an article in *Results in Pharma Sciences* is taken to imply that the authors are prepared to freely distribute materials used in the published experiments (e.g. antibodies, cell lines) to academic researchers for their own use.

### **Conflict of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also <https://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://service.elsevier.com/app/answers/detail/a\\_id/286/supporthub/publishing](http://service.elsevier.com/app/answers/detail/a_id/286/supporthub/publishing).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <https://www.elsevier.com/sharingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <https://www.elsevier.com/editors/plagdetect>.

### **Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

**Please note that after the accepted manuscript is published online** any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Reporting clinical trials**

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

### **Registration of clinical trials**

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is

defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <https://www.elsevier.com/OAauthoragreement>). Permitted third party reuse of open access articles is determined by the author's choice of user license (see <https://www.elsevier.com/openaccesslicenses>).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. For more information on author rights please see <https://www.elsevier.com/copyright>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about existing agreements please visit <https://www.elsevier.com/fundingbodies>.

### **Open access**

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative Commons user licenses (see <https://www.elsevier.com/openaccesslicenses>):

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 1500**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <https://www.elsevier.com/patient-consent-policy>. Unless

you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### **Chemical compounds**

You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the PubChem CID of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). The PubChem CIDs can be found via <http://www.ncbi.nlm.nih.gov/pccompound>. Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below:

Chemical compounds studied in this article

Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)

More information is available at: <https://www.elsevier.com/PubChem>.

### **Reference management software**

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles (<http://citationstyles.org>), such as Mendeley (<http://www.mendeley.com/features/reference-manager>) and Zotero (<https://www.zotero.org/>), as well as EndNote (<http://endnote.com/downloads/styles>). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/results-in-pharma-sciences>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <https://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Database linking**

Elsevier encourages authors to connect articles with external databases, giving readers access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <https://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows:

doi:10.1016/j.jconrel.2010.11.031

When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

### **Author inquiries**

For inquiries relating to *Results in Pharma Sciences* please contact the Managing Editor of *Results in Pharma Sciences* at: [rinphs@elsevier.com](mailto:rinphs@elsevier.com). You can track accepted articles at <http://www.elsevier.com/trackarticle> and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

© Copyright 2014 Elsevier | <http://www.elsevier.com>